Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

Table 3 Analysis of the association between thrombocytosis and clinicopathological parameters of endometrial carcinoma

Clinicopathological characteristics	Number of studies	Model	OR (95% CI)	I² (%)	P _h	Z	P
FIGO stage (III-IV vs. I-II)	5	Random	3.24 (1.78–5.88)	58.1	0.049	3.86	< 0.001
Grade (2–3 vs.1)	6	Fixed	1.89 (1.30–2.76)	19.4	0.287	3.32	0.001
LVSI (yes vs. no)	5	Fixed	1.98 (1.34–2.94)	0	0.603	3.4	0.001
Histological type (non-endometrioid vs. endometrioid)	5	Random	1.45 (0.76–2.77)	60.6	0.038	1.11	0.265
LN metastasis (yes vs. no)	2	Fixed	3.13 (1.71–5.75)	0	0.416	3.69	< 0.001
Recurrence (yes vs. no)	2	Fixed	8.57 (3.71–19.83)	0	0.458	5.02	< 0.001
VTE (yes vs. no)	2	Fixed	6.45 (4.06–10.24)	0	0.807	7.91	< 0.001

Random-effects model was used when P-value for heterogeneity test < 0.1; otherwise, fixed-effects model was used
Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LVSI lymphovascular space invasion, LN lymph node, VTE venous thromboembolism, OR odds ratio, CI confidence interval, P_h, P-value for heterogeneity based on Q test, P P-value for statistical significance based on Z test

ISSN: 1471-2407